404 related articles for article (PubMed ID: 33880555)
1. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
Tawbi HA; Forsyth PA; Hodi FS; Lao CD; Moschos SJ; Hamid O; Atkins MB; Lewis K; Thomas RP; Glaspy JA; Jang S; Algazi AP; Khushalani NI; Postow MA; Pavlick AC; Ernstoff MS; Reardon DA; Puzanov I; Kudchadkar RR; Tarhini AA; Sumbul A; Rizzo JI; Margolin KA
Neuro Oncol; 2021 Nov; 23(11):1961-1973. PubMed ID: 33880555
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
Tawbi HA; Forsyth PA; Hodi FS; Algazi AP; Hamid O; Lao CD; Moschos SJ; Atkins MB; Lewis K; Postow MA; Thomas RP; Glaspy J; Jang S; Khushalani NI; Pavlick AC; Ernstoff MS; Reardon DA; Kudchadkar R; Tarhini A; Chung C; Ritchings C; Durani P; Askelson M; Puzanov I; Margolin KA
Lancet Oncol; 2021 Dec; 22(12):1692-1704. PubMed ID: 34774225
[TBL] [Abstract][Full Text] [Related]
3. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Tawbi HA; Forsyth PA; Algazi A; Hamid O; Hodi FS; Moschos SJ; Khushalani NI; Lewis K; Lao CD; Postow MA; Atkins MB; Ernstoff MS; Reardon DA; Puzanov I; Kudchadkar RR; Thomas RP; Tarhini A; Pavlick AC; Jiang J; Avila A; Demelo S; Margolin K
N Engl J Med; 2018 Aug; 379(8):722-730. PubMed ID: 30134131
[TBL] [Abstract][Full Text] [Related]
4. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis.
Su M; Yang Y; Wang P
Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):761-769. PubMed ID: 37228242
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids.
Manacorda S; Carmena MT; Malone C; Linh Le HM; Furness AJS; Larkin J; Schmitt AM
Eur J Cancer; 2023 Jul; 188():98-107. PubMed ID: 37229837
[TBL] [Abstract][Full Text] [Related]
9. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Wolchok JD; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Butler MO; Hill A; Márquez-Rodas I; Haanen JBAG; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bas T; Ritchings C; Larkin J; Hodi FS
J Clin Oncol; 2022 Jan; 40(2):127-137. PubMed ID: 34818112
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.
Thompson JR; Lai-Kwon J; Morton RL; Guminski AD; Gonzalez M; Atkinson V; Sandhu S; Brown MP; Menzies AM; McArthur GA; Lo SN; Long GV; Bartula I
Immunotherapy; 2023 Jun; 15(8):593-610. PubMed ID: 37132182
[TBL] [Abstract][Full Text] [Related]
12. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M; Ciuleanu TE; Lee JS; Schenker M; Zurawski B; Kim SW; Mahave M; Alexandru A; Peters S; Pluzanski A; Caro RB; Linardou H; Burgers JA; Nishio M; Martinez-Marti A; Azuma K; Axelrod R; Paz-Ares LG; Ramalingam SS; Borghaei H; O'Byrne KJ; Li L; Bushong J; Gupta RG; Grootendorst DJ; Eccles LJ; Brahmer JR
J Thorac Oncol; 2023 Aug; 18(8):1055-1069. PubMed ID: 37146754
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
14. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Rezazadeh Kalebasty A; George DJ; Hutson TE; Arrowsmith ER; Zhang J; Zoco J; Johansen JL; Leung DK; Tykodi SS
Cancer; 2022 Mar; 128(5):966-974. PubMed ID: 34784056
[TBL] [Abstract][Full Text] [Related]
16. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
van Zeijl MCT; van Breeschoten J; de Wreede LC; Wouters MWJM; Hilarius DL; Blank CU; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Stevense-den Boer MA; van der Veldt AAM; Vreugdenhil G; Boers-Sonderen MJ; Suijkerbuijk KPM; Haanen JBAG; van den Eertwegh AJM
J Immunother; 2023 Jun; 46(5):197-204. PubMed ID: 37103470
[TBL] [Abstract][Full Text] [Related]
17. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Reck M; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Reyes F; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; Paz-Ares L; Carbone DP; Memaj A; Marimuthu S; Zhang X; Tran P; John T
ESMO Open; 2021 Oct; 6(5):100273. PubMed ID: 34607285
[TBL] [Abstract][Full Text] [Related]
18. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hogg D; Hill A; Márquez-Rodas I; Haanen J; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bastholt L; Rizzo JI; Balogh A; Moshyk A; Hodi FS; Wolchok JD
N Engl J Med; 2019 Oct; 381(16):1535-1546. PubMed ID: 31562797
[TBL] [Abstract][Full Text] [Related]
19. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
